Emergent BioSolutions (EBS) Gross Profit (2011 - 2026)

Emergent BioSolutions' Gross Profit history runs 16 years deep, the most recent figure standing at $84.1 million for Q1 2026.

• In Q1 2026, Gross Profit fell 37.1% year-over-year to $84.1 million; the TTM figure through Mar 2026 stood at $367.1 million (down 3.8% YoY), while the FY2025 annual figure was $416.7 million, up 15.02% from the prior year.
• Gross Profit was $84.1 million for Q1 2026 at Emergent BioSolutions, up from $63.8 million in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $303.9 million in Q1 2022 to a low of $11.4 million in Q1 2023.
• Historically, Gross Profit has averaged $127.1 million across 5 years, with a median of $139.4 million in 2025.
• The sharpest annual moves came in 2023 and 2024: Gross Profit slumped 96.25% in 2023, then jumped 1266.67% in 2024.
• A 5-year view of Gross Profit shows it stood at $162.9 million in 2022, then sank by 43.83% to $91.5 million in 2023, then retreated by 16.17% to $76.7 million in 2024, then retreated by 16.82% to $63.8 million in 2025, then jumped by 31.82% to $84.1 million in 2026.
• The last three Gross Profit figures came in at $84.1 million (Q1 2026), $63.8 million (Q4 2025), and $145.2 million (Q3 2025), per Business Quant data.